Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
Recursion Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Recursion Pharmaceuticals
Recursion Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?